The Joint Corp. (NASDAQ: JYNT) reported Q3 EPS of ($0.05), $0.07 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $29.5 million versus the consensus estimate of $29.06 million.

2023 Guidance :
For 2023, management reiterated financial and clinic opening guidance.

Revenue is expected to be between $115.0 million and $118.0 million,versus the consensus of $115.8 million and compared to $101.9 million in 2022.
Adjusted EBITDA is expected to be between $11.0 million and $12.5 million, compared to $11.5 million in 2022.
Franchised clinic openings are expected to be between 100 and 120, compared to 121 in 2022.
Company-owned or managed greenfield clinic openings are expected to be between 8 and 12, compared to 16 in 2022.

For earnings history and earnings-related data on The Joint Corp. (JYNT) click here.